June 15, 2018
UT Southwestern doctors see a nearly threefold improvement in wound closures
Foot ulcers are a common and potentially serious complication for people with diabetes. Even with proper wound care, chronic diabetic foot ulcers often are difficult to treat – and can lead to amputation of the toes, feet, and legs.
But a novel therapy – the use of viable cryopreserved placental membranes (vCPMs) – may help change this.
In a randomized trial of 360 patients with 441 wounds, doctors from UT Southwestern Medical Center and several partner institutions found that treating diabetic foot ulcers with these specially preserved membranes significantly improves wound closures (62 percent) when compared to standard “good wound care” (21 percent) within a 12-week period.
The results of the multicenter trial (“Effectiveness of viable cryopreserved placental membranes for management of diabetic foot ulcers in a real world setting”) were published in the April 23 issue of Wound Repair and Regeneration.
These findings corroborate the results of previous randomized studies in supporting the benefits of using vCPMs to manage diabetic foot ulcers. The findings also can influence policy and treatment decisions regarding the use of advanced vCPM technology.
“Improving the treatment – and therefore the healing – of diabetic foot ulcers goes a long way in reducing infection, hospitalizations, and preventing amputations,” says study co-author Katherine Raspovic, D.P.M., an assistant professor in UT Southwestern’s Department of Orthopaedic Surgery.
“While more research on the use of viable cryopreserved placental membranes is needed, those of us who treat patients with diabetic foot conditions are very encouraged by these results.”
Additional co-authors include UT Southwestern Professor and Chairman of the Department of Orthopaedic Surgery, Dane Wukich, M.D., and Lawrence Lavery, D.P.M., M.P.H., Professor, Department of Plastic Surgery.